Comparison of Efficacy of Hyperthermic Intraperitoneal Chemotherapeutics Mitomycin C versus Oxaliplatin in Experimental Colorectal Peritoneal Metastasis Model

Abstract

Comparison of Efficacy of Hyperthermic Intraperitoneal Chemotherapeutics Mitomycin C versus Oxaliplatin in Experimental Colorectal Peritoneal Metastasis Model

Abstract

Aim: Our study aimed to establish a mouse model with colorectal cancer-induced peritoneal metastasis(PM) and to compare the efficacy of hyperthermic intraperitoneal chemotherapeutic agents, mitomycin C and oxaliplatin. Materials and Methods: The peritoneal metastasis model was established in nude mice using the CC531 colon carcinoma cell line. Models with PM were randomized into four groups of seven animals each: Group-1, control group; Group-2, hyperthermic intraperitoneal chemotherapy(HIPEC) with mitomycin C(MMC), and Group-3, HIPEC with Oxaliplatin(OXA). Results: Tumor development was achieved in all animals. While the tumor burden decreased significantly in the treatment Group-2(p=.013). In the PM mouse model, hyperthermic intraperitoneal administration of MMC had a higher tumoricidal effect than hyperthermic intraperitoneal administration of OXA. Conclusions: Our PM model provided a good opportunity to examine the efficacy of HIPEC and IPIP. Hyperethermic intraperitoneal mitomycin applied in the colorectal PM animal model was found to have higher tumoricidal activity than oxaliplatin. In future studies, we plan to evaluate efficacies of different drugs in the PM models we have created.

Keywords

• peritoneal metastasis model
• colorectal cancer
• HIPEC

References

1. World Health Organization GLOBOCAN database https://gco.iarc.fr/today/ home. Accessed 8 Mar 2021.
2. Jayne D.G., Fook S., Loi C., Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002;89:1545–50.
3. Macrì A., Saladino E., Bartolo V, et al. Peritoneal carcinomatosis of colorectal origin. World J Gastrointest Oncol 2010;2:98-101.
4. Sadeghi B., Arvieux C., Glehen O, et al. Peritoneal carcinomatosis from non gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer 200;88:358-363.
5. Lemmens V.E., Klaver Y.L., Verwaal V.J., Rutten H.J., Coebergh J.W., Hingh I.H. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 2011;128:2717–25.
6. Segelman J., Granath F., Holm T., Machado M., Mahteme H., Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 2012;99:699–705.
7. Thomassen I., van Gestel Y.R., Lemmens V.E., de Hingh I.H. Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin. Dis Colon Rectum 2013;56:1373–80.
8. Enblad M, Graf W, Birgisson H. Risk factors for appendiceal and colorectal peritoneal metastases. Eur J Surg Oncol 2018;44:997–1005.

9. Esquivel J., Lowy A.M., Markman M. et al. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. Ann Surg Oncol 2014;21:4195-4201.
10. Li Y, Yu Y, Liu Y. Report on the 9th international congress on peritoneal surface malignancies. Cancer Biol Med 2014;11:281-284.
11. Pelz J.O., Doerfer J., Hohenberger W., Meyer T.: A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis. BMC cancer 2005;5:1.
12. Jacquet P., and Sugarbaker P.H.: Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In peritoneal carcinomatosis: principles of management. Springer US; Cancer Treat Res 1996;82:359-374.
13. Witkamp A.J., van Coevorden F., Kaag M.M. et al: Dose finding study of hyperthermic intraperitoneal chemotherapy with mitomycin C in patients with carcinosis of colorectal origin. Eur J Surg Oncol 1998;24:18.
14. Cheung M.C., Spalding P.B., Gutierrez J.C. et al. Body surface area prediction in normal, hypermuscular, and obese mice. J Surg Res 2009;153:326-331.
15. Spratt J.S., Adcock R.A., Muskovin M., Sherrilll W., McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980;40:256-60.
16. Sugarbaker P.H. Peritonectomy procedures. Ann Surg 1995;221:29–42.
17. Franko J., Shi Q., Goldman C.D. et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of North central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 2012;30:263–7.
18. Glehen O., Kwiatkowski F., Sugarbaker P.H. et al.Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22:3284-92.
19. Glehen O, Mohamed F, Sugarbaker P.H.: Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 2004;240(2):278-85.
20. Van Ruth S, Verwaal V.J., Hart A.A., van Slooten G.W., Zoetmulder F.A.: Heat penetration in locally applied hyperthermia in the abdomen during intra-postoperative hyperthermic intraperitoneal chemotherapy. Anticancer Res 2003;23:1501-8.
21. Veenhuizen R.B., Marijnissen J.P., Kenemans P. et al. Intraperitoneal photodynamic therapy of the rat CC531 adenocarcinoma. Br J Cancer 1996; 73(11):1387-92.
22. Yao Y., Zhou Y., Su X. et al. Establishment and Characterization of intraperitoneal xenograft models by co-injection of human tumor cells and extracellular matrix gel. Oncol Lett 2015;10(6):3450-3456.
23. Bastiaenen V.P., Klaver C.E.L., van der Heijden M.C.S. et al. A mouse model for peritoneal metastases of colorectal origin recapitulates patient heterogeneity. Lab Invest 2020;100(11):1465-1474.
24. Los G., Mutsaers P.H., van der Vijgh W.J., Baldew G.S., de Graaf P.W., McVie J.G. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989;49:3380-4.
25. Los G., Sminia P., Wondergem J. et al. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 1991;27:472-7.
26. Liesenfeld L.F., Hillebrecht H.C., Klose J., Schmidt T., Schneider M. Impact of Perfusate Concentration on HIPEC Efficacy and Toxicity in a Rodent Model. J Surg Res 2020;253:262-271.
27. Kusamura S, Dominique E, Baratti D, Younan R, Deraco M. Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. Journal of Surgical Oncology 2008;98(4):247-52 Sugarbaker P.H., Van der Speeten K., Stuart O.A. Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer. World J Gastrointest Oncol 2010;2(1):19-30. Elias D., Bonnay M., Puizillou J. et al. Heated intra operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Annals of Oncology 2002;13(2):267-72.
28. Guo Y., Xiong B.H., Zhang T., Cheng Y., Ma L. XELOX vs. FOLFOX in metastatic colorectal cancer: an updated meta-analysis. Cancer Investig 2016;34(2):94–104
29. Zhang X., Wu Q., Wei M., Deng X., Gu C., Wang Z. Oxaliplatin versus mitomycin C in HIPEC for peritoneal metastasis from colorectal cancer: a systematic review and meta-analysis of comparative studies. Int J Colorectal Dis 2020;35(10):1831-1839.
30. Wisselink D.D., Braakhuis L.L.F., Gallo G. et al. Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer. Crit Rev Oncol Hematol 2019;142:119–129.
31. Leung V., Huo Y.R., Liauw W., Morris D.L. Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. Eur J Surg Oncol 2017;43(1):144-149.
32. Eden W. J. V., Kok N.F.M, Woensdregt K, Huitema A.D.R, Boot H., Aalbers A.G.J. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. Eur J Surg Oncol 2018;44(2):220-227.
33. Delhorme J P, Sauvinet G, Séverac F. et al. Peritoneal Metastases of Colorectal Origin Treated with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: The Efficiency of Mitomycin C. Ann Surg Oncol 2022;29(12):7568-7576.
34. Villaverde A.P., Esquivel J., Lowy A.M. et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol 2014;110(7):779-85.
35. Woeste M.R., Philips P., Egger M.E., Scoggins C.R., McMasters K.M., Martin R.C.G. Optimal perfusion chemotherapy: A prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy inmetastatic colon cancer. J Surg Oncol 2020;121:1298–305.
36. Raue W., Kilian M., Braumann C, et al. Multimodal approach for treatment of peritoneal surface malignancies in a tumour-bearing rat model. Int J Colorectal Dis 2010;25(2):245-50.